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Introduction {#jah31971-sec-0004}
============

The 2014 American College of Cardiology/American Heart Association guidelines recommend consideration of beta‐blocker initiation for patients with inducible ischemia on stress testing or with a Revised Cardiac Risk Index of ≥3.[1](#jah31971-bib-0001){ref-type="ref"} In addition, the European Society of Cardiology guidelines suggest that preoperative initiation of beta‐blockers may be considered for patients scheduled for high‐risk surgery and who have 2 clinical risk factors or American Society of Anesthesiology Physical Status Classification status of 3.[2](#jah31971-bib-0002){ref-type="ref"} Patients with diabetes mellitus (DM) have an increased risk of substantial mortality, similar to those with coronary heart disease (CHD) without DM.[3](#jah31971-bib-0003){ref-type="ref"}, [4](#jah31971-bib-0004){ref-type="ref"}, [5](#jah31971-bib-0005){ref-type="ref"}, [6](#jah31971-bib-0006){ref-type="ref"} DM is thus regarded as a CHD risk equivalent and should be treated as aggressively as CHD.[7](#jah31971-bib-0007){ref-type="ref"} Current guidelines, however, do not provide strong recommendations for perioperative beta‐blocker therapy for patients with DM because of limited evidence.

The results of a multicenter study suggested that this therapy conferred a significant survival benefit for patients with CHD and DM, but the study did not focus specifically on patients with DM.[8](#jah31971-bib-0008){ref-type="ref"} In contrast, the Diabetes Postoperative Mortality and Morbidity (DIPOM) trial,[9](#jah31971-bib-0009){ref-type="ref"} which involved 921 patients with DM, showed that perioperative metoprolol administration did not significantly affect mortality. These controversial findings have raised concern about the beneficial effects of perioperative beta‐blocker therapy in patients with DM undergoing noncardiac surgery. Furthermore, the timing of beta‐blocker initiation before such surgery may influence the survival benefit, but this factor has not been addressed. Compared with longer durations of preoperative beta‐blocker therapy, previous studies have shown that shorter durations tend to be associated with worse outcomes.[10](#jah31971-bib-0010){ref-type="ref"}, [11](#jah31971-bib-0011){ref-type="ref"}, [12](#jah31971-bib-0012){ref-type="ref"}

In light of these controversial findings and the knowledge gap regarding the timing of beta‐blocker initiation in patients with DM, we conducted a nationwide population‐based study of the Taiwanese population with DM covering the period 2000 to 2011 (the largest scale study to date), with the primary objective of exploring the effects of the time of initiation of beta‐blockers and subsequent mortality among patients with DM undergoing noncardiac surgery in real‐world scenarios.

Methods {#jah31971-sec-0005}
=======

Data Source {#jah31971-sec-0006}
-----------

Taiwan\'s National Health Insurance (NHI) program, launched in 1995, provides comprehensive medical coverage (including outpatient care, emergency room and hospital care, dental services, laboratory and medical examinations, drug prescriptions, and surgical and interventional procedures) and is universally available to all citizens. As part of the national health care reimbursement scheme, NHI enrollment is mandatory and required by law. In 2007, ≈98.4% of Taiwan\'s 22.96 million citizens were registered and enrolled. The Taiwanese government releases linked health care registry data for research purposes. In the current study, we used the Longitudinal Cohort of Diabetes Patients data set, which consists of deidentified secondary data from a random sample of 120 000 patients with the diagnosis of DM in each year since 1999 and has been validated previously.[13](#jah31971-bib-0013){ref-type="ref"} For privacy purposes, all personal identifiers were encrypted before release of the data set to researchers, with unique numbers used for linking of individuals\' data. Medical diagnoses were classified using International Classification of Diseases, Ninth Revision, Clinical Modification codes, and surgical procedures were coded according to the NHI classification system. The institutional review board of Taipei City Hospital exempted this study from full review (TCHIRB‐10404107‐W) because the sample comprised deidentified secondary data.

Study Design {#jah31971-sec-0007}
------------

This population‐based observational cohort study aimed to investigate the associations of different beta‐blocker initiation times with subsequent mortality in patients with DM undergoing noncardiac surgery. We included all patients aged ≥20 years with the diagnosis of DM and hospitalization for noncardiac surgery between January 2000 and December 2011. Noncardiac surgery was classified according to surgical specialty and extent as *vascular, orthopedic, abdominal, thoracic*, or *other* surgery. Patients undergoing \>1 type of surgery and those with previous history of cardiac surgery were excluded from our analysis. The exposures of interest were beta‐blockers (including acebutolol, alprenolol, atenolol, bisoprolol, carteolol, carvedilol, labetalol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, and timolol). Based on the beta‐blocker type used before noncardiac surgery, we stratified patients into the beta‐blocker and non--beta‐blocker cohorts. We assigned patients receiving atenolol, bisoprolol, metoprolol, or carvedilol to *cardioprotective* beta‐blocker users because these beta‐blockers have been proven to be beneficial in patients with ischemic heart disease or congestive heart failure and may be associated with improved outcomes in patients undergoing noncardiac surgery.[14](#jah31971-bib-0014){ref-type="ref"}, [15](#jah31971-bib-0015){ref-type="ref"}, [16](#jah31971-bib-0016){ref-type="ref"}, [17](#jah31971-bib-0017){ref-type="ref"}, [18](#jah31971-bib-0018){ref-type="ref"} Patients using all other beta‐blockers were assigned to *other* beta‐blocker users. We extracted data on beta‐blocker prescriptions before hospital admission and dichotomized beta‐blocker initiation timing into 2 periods (\>30 and ≤30 days).

To examine the clinical characteristics of the study population, we extracted demographic variables, diagnostic and surgical procedure codes, socioeconomic information (including monthly income and urbanization level \[4 levels, 1=urban and 4=rural\]), number of outpatient visits in the past year, Charlson Comorbidity Index,[19](#jah31971-bib-0019){ref-type="ref"} revised cardiac risk index (including 6 variables: high‐risk surgery, cerebrovascular disease, ischemic heart disease, congestive heart failure, DM, and renal insufficiency),[20](#jah31971-bib-0020){ref-type="ref"}, [21](#jah31971-bib-0021){ref-type="ref"} and adapted Diabetes Complications Severity Index for the severity of DM.[22](#jah31971-bib-0022){ref-type="ref"}, [23](#jah31971-bib-0023){ref-type="ref"}, [24](#jah31971-bib-0024){ref-type="ref"} We also identified other comorbidities related to general health and treatment with concomitant medications, including antidiabetic drugs, alpha‐blockers, angiotensin‐converting‐enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, diuretics, other antihypertensive drugs, aspirin, clopidogrel, ticlopidine, warfarin, dipyridamole, nitrates, and statins.

Propensity Score Matching {#jah31971-sec-0008}
-------------------------

Because indication bias may have been introduced based on the use of beta‐blockers, we performed a propensity score analysis to adjust for baseline imbalances among cohorts, including baseline comorbidities and concomitant medications that may confound the association between treatment and outcomes of interest. We used the propensity score analysis to match each participant in the beta‐blocker cohort to 1 patient in the non--beta‐blocker cohort respectively according to the closest propensity score for any beta‐blocker use, using nearest neighbor matching without replacement and calipers of width equal to 0.1 SD of the logit of the propensity score. The details of the propensity score model (Table S1) and the distribution of the propensity scores before and after propensity score matching (Figure S1) are provided.[25](#jah31971-bib-0025){ref-type="ref"} The 30‐day mortality started at the time of discharge from the hospital. In‐hospital mortality was also the outcome of interest.

Statistical Analysis {#jah31971-sec-0009}
--------------------

We used descriptive statistics (means, SDs, and frequencies) for basic characterization of the study population. Standardized mean differences were used to compare baseline characteristics among groups. We performed conditional logistic regression analysis to calculate odds ratios (ORs) for comparison of outcomes among groups. The likelihood ratio test was used to detect interaction with covariates (including age, sex, hypertension, dyslipidemia, cerebrovascular disease, myocardial infarction, heart failure, chronic kidney disease, revised cardiac risk index, and vascular surgery), and subgroup analyses were performed accordingly.

We used Microsoft SQL Server 2012 (Microsoft Corp) for data linkage, processing, and sampling. The algorithm of propensity score matching was applied using SAS software (version 9.3; SAS Institute Inc). All other statistical analyses were performed using Stata statistical software (version 13.0; StataCorp). All 2‐tailed *P* values \<0.05 were considered to be statistically significant.

Results {#jah31971-sec-0010}
=======

Characteristics of the Study Population {#jah31971-sec-0011}
---------------------------------------

For the study period of January 2000 to December 2011, a total of 452 220 patients with DM undergoing noncardiac surgery were enrolled. After propensity score matching, we identified 50 952 beta‐blocker users and 50 952 matched controls. Mean age in the beta‐blocker and matched cohorts was 64.4 years (SD 12.2 years). Women were slightly predominant (53.1%). Among all participants, 27.1% of patients underwent high‐risk surgery. Detailed characteristics of the cohorts before (Table S2) and after (Table [1](#jah31971-tbl-0001){ref-type="table-wrap"}) propensity score matching are presented.

###### 

Baseline Characteristics of Diabetes Mellitus Patients After Propensity Score Matching

  Characteristics                                                                             Beta‐Blockade Cohort   Control Cohort   StD[a](#jah31971-note-0004){ref-type="fn"}
  ------------------------------------------------------------------------------------------- ---------------------- ---------------- --------------------------------------------
  Patient, n                                                                                  50 952                 50 952           
  Mean age (SD), y                                                                            64.4 (12.2)            64.4 (12.2)      0.000
  Male                                                                                        23 857 (46.8)          23 857 (46.8)    0.000
  Monthly income, NT\$                                                                                                                
  Dependent                                                                                   17 403 (34.2)          17 451 (34.2)    −0.002
  \<19 100                                                                                    10 612 (20.8)          10 589 (20.8)    0.001
  19 100 to 41 999                                                                            20 456 (40.1)          20 422 (40.1)    0.001
  ≥42 000                                                                                     2481 (4.9)             2490 (4.9)       −0.001
  Urbanization[b](#jah31971-note-0005){ref-type="fn"}                                                                                 
  Level 1                                                                                     17 611 (34.6)          17 594 (34.5)    0.001
  Level 2                                                                                     30 486 (59.8)          30 505 (59.9)    −0.001
  Level 3                                                                                     2414 (4.7)             2405 (4.7)       0.001
  Level 4 (rural area)                                                                        441 (0.9)              448 (0.9)        −0.001
  Outpatient visits, in the past 1 year                                                                                               
  0--5 visits                                                                                 456 (0.9)              461 (0.9)        −0.001
  6--10 visits                                                                                1915 (3.8)             1915 (3.8)       0.000
  11--15 visits                                                                               3994 (7.8)             3982 (7.8)       0.001
  \>15 visits                                                                                 44 587 (87.5)          44 594 (87.5)    0.000
  Charlson Comorbidity Index[c](#jah31971-note-0006){ref-type="fn"} (SD)                      7.5 (3.1)              7.5 (3.2)        0.000
  Adapted Diabetes Complications Severity Index[d](#jah31971-note-0007){ref-type="fn"} (SD)   2.9 (2.4)              2.9 (2.5)        0.001
  Duration of diabetes mellitus, months (SD)                                                  47.5 (38.4)            47.6 (38.4)      −0.001
  Revised cardiac risk index                                                                                                          
  High‐risk surgery                                                                           13 807 (27.1)          13 798 (27.1)    0.000
  Ischemia heart disease                                                                      29 093 (57.1)          29 020 (57.0)    0.003
  Cerebrovascular disease                                                                     480 (0.9)              478 (0.9)        0.000
  Heart failure                                                                               10 288 (20.2)          10 279 (20.2)    0.000
  Renal insufficiency                                                                         786 (1.5)              781 (1.5)        0.001
  Type of procedure                                                                                                                   
  Vascular                                                                                    4716 (9.3)             4673 (9.2)       0.003
  Orthopedic                                                                                  13 616 (26.7)          13 645 (26.8)    −0.001
  Abdominal                                                                                   8385 (16.5)            8370 (16.4)      0.001
  Thoracic                                                                                    1046 (2.1)             1045 (2.1)       0.000
  Other                                                                                       23 189 (45.5)          23 219 (45.6)    −0.001
  Concomitant medications                                                                                                             
   Antidiabetic drugs                                                                                                                 
  Acarbose inhibits enzymes                                                                   2263 (4.4)             2276 (4.5)       −0.001
  Sulfonylurea                                                                                12 406 (24.3)          12 406 (24.3)    −0.002
  Insulin                                                                                     1770 (3.5)             1787 (3.5)       −0.002
  Metformin                                                                                   14 047 (27.6)          14 127 (27.7)    −0.004
  Thiazolidinediones                                                                          2071 (4.1)             2086 (4.1)       −0.001
  Glinide                                                                                     1906 (3.7)             1929 (3.8)       −0.002
  Dipeptidyl peptidase 4 inhibitor                                                            765 (1.5)              765 (1.5)        0.000
   Antihypertensive drug                                                                                                              
  Alpha‐blocker                                                                               3320 (6.5)             3290 (6.5)       0.002
  ACEI or ARB                                                                                 20 645 (40.5)          20 703 (40.6)    −0.002
  Calcium channel blocker                                                                     25 905 (50.8)          25 959 (50.9)    −0.002
  Diuretics                                                                                   14 284 (28.0)          14 269 (28.0)    0.001
  Other antihypertensive drug                                                                 1670 (3.3)             1665 (3.3)       0.001
  Aspirin                                                                                     14 685 (28.8)          14 646 (28.7)    0.002
  Clopidogrel                                                                                 1527 (3.0)             1499 (2.9)       0.003
  Ticlopidine                                                                                 777 (1.5)              773 (1.5)        0.001
  Warfarin                                                                                    621 (1.2)              624 (1.2)        −0.001
  Dipyridamole                                                                                4822 (9.5)             4803 (9.4)       0.001
  Nitrate                                                                                     5646 (11.1)            5549 (10.9)      0.006
  Statin                                                                                      10 722 (21.0)          10 742 (21.1)    −0.001
  Comorbidities                                                                                                                       
  Hypertension                                                                                46 624 (91.5)          46 673 (91.6)    −0.003
  Peripheral vascular disease                                                                 3560 (7.0)             3569 (7.0)       −0.001
  Atrial fibrillation                                                                         2678 (5.3)             2652 (5.2)       0.002
  Dyslipidemia                                                                                32 953 (64.7)          32 962 (64.7)    0.000
  Valvular heart disease                                                                      7597 (14.9)            7527 (14.8)      0.004
  Cancer                                                                                      8007 (15.7)            8019 (15.7)      −0.001
  Autoimmune disease                                                                          2607 (5.1)             2610 (5.1)       0.000
  Physical limitation                                                                         5311 (10.4)            5357 (10.5)      −0.003
  Propensity score (SD)                                                                       0.30 (0.16)            0.30 (0.16)      0.002

All data were described as number (%), except mean age and propensity score. ACEI indicates angiotensin‐converting‐enzyme inhibitor; ARB, angiotensin II receptor blockers; StD, standardized difference.

Imbalance defined as absolute value \>0.015.

Urbanization levels in Taiwan are divided into 4 strata according to the Taiwan National Health Research Institute publications. Level 1 designates the most urbanized areas, and level 4 designates the least urbanized areas.

Charlson Comorbidity Index is used to determine overall systemic health. With each increased level of the index, there are stepwise increases in the cumulative mortality~.~

The adapted Diabetes Complications Severity Index is a 13‐point scale with 7 complication categories (retinopathy, nephropathy, neuropathy, cerebrovascular, cardiovascular, peripheral vascular disease, and metabolic, sum of 7 diabetes complications without severity grading; range 0‐7). Each complication produced a numeric score ranging from 0 to 2 (0=no abnormality, 1=some abnormality, 2=severe abnormality).

Associations Between Perioperative Beta‐Blocker Use and In‐Hospital and 30‐Day Mortality Risks {#jah31971-sec-0012}
----------------------------------------------------------------------------------------------

Compared with the matched controls, the beta‐blocker cohort was associated with lower risks of in‐hospital mortality (OR 0.83, 95% CI 0.78--0.90) and 30‐day mortality (OR 0.83, 95% CI 0.79--0.89) (Table [2](#jah31971-tbl-0002){ref-type="table-wrap"}). In addition, we assessed the effects of beta‐blockers on cardiovascular risks and found a trend, albeit not significant, toward reduced risk of myocardial infarction (OR 0.76, 95% CI 0.42--1.38) but increased risk of stroke (OR 1.33, 95% CI 0.94--1.88) in beta‐blocker users compared with matched controls.

###### 

Odds Ratios of Effect of Perioperative Beta‐Blockade on Mortality Among Patients With Diabetes Mellitus Undergoing Noncardiac Surgery After Propensity Score Matching

                                                                Beta‐Blocker Cohort   Matched Control Cohort   Propensity Score Matching             
  ------------------------------------------------------------- --------------------- ------------------------ --------------------------- --------- ---------
  In hospital mortality                                                                                                                              
  All beta‐blockade                                             1512                  1795                     0.83 (0.78--0.90)           \<0.001   \<0.001
  Atenolol, bisoprolol, carvedilol, and metoprolol (n=31 957)   872                   1156                     0.75 (0.68--0.82)           \<0.001   
  Other beta‐blockade (n=18 995)                                640                   639                      1.00 (0.90--1.12)           0.977     
  30‐day mortality                                                                                                                                   
  All beta‐blockade                                             2099                  2494                     0.83 (0.79--0.89)           \<0.001   \<0.001
  Atenolol, bisoprolol, carvedilol, and metoprolol (n=31 957)   1234                  1621                     0.75 (0.70--0.81)           \<0.001   
  Other beta‐blockade (n=18 995)                                865                   873                      0.99 (0.90--1.09)           0.844     

In further analyses, use of cardioprotective beta‐blockers was associated with lower risks of in‐hospital mortality (OR 0.75, 95% CI 0.68--0.82) and 30‐day mortality (OR 0.75, 95% CI 0.70--0.81). However, use of other beta‐blockers was not associated with the decreased risk of in‐hospital mortality (OR 1.00, 95% CI 0.90--1.12) or 30‐day mortality (OR 0.99, 95% CI 0.90--1.09). Similar results were found before propensity score matching (Table S3).

Associations Between Perioperative Beta‐Blocker Initiation Time and In‐Hospital and 30‐Day Mortality Risks {#jah31971-sec-0013}
----------------------------------------------------------------------------------------------------------

In analyses stratified according to perioperative initiation time of cardioprotective beta‐blockers, only the use of the beta‐blockers for \>30 days before surgery was associated with lower risks of in‐hospital mortality (OR 0.72, 95% CI 0.65--0.78, *P* ~interaction~=0.002) and 30‐day mortality (OR 0.72, 95% CI 0.66--0.78, *P* ~interaction~\<0.001) (Table [3](#jah31971-tbl-0003){ref-type="table-wrap"}). When we stratified the risk of mortality associated with different subtypes of cardioprotective beta‐blockers, we found that only atenolol and bisoprolol were associated with lower risks of in‐hospital mortality (Table [4](#jah31971-tbl-0004){ref-type="table-wrap"}). For the longer period of outcomes, atenolol, bisoprolol, and metoprolol were associated with lower risks of 30‐day mortality, whereas carvedilol was not associated with such reduced risk.

###### 

Effect of Different Duration of Perioperative Atenolol, Bisoprolol, Carvedilol, and Metoprolol Use on Mortality Among Patients With Diabetes Mellitus Undergoing Noncardiac Surgery

                          Beta‐Blocker Cohort   Matched Control Cohort   Propensity Score Matching             
  ----------------------- --------------------- ------------------------ --------------------------- --------- ---------
  In‐hospital mortality                                                                                        
  All                     872/31 957            1156/31 957              0.75 (0.68--0.82)           \<0.001   0.002
  Use for ≤30 days        99/2468               85/2468                  1.17 (0.87--1.57)           0.293     
  Use for \>30 days       773/29 489            1071/29 489              0.72 (0.65--0.78)           \<0.001   
  30‐day mortality                                                                                             
  All                     1234/31 957           1621/31 957              0.75 (0.70--0.81)           \<0.001   \<0.001
  Use for ≤30 days        142/2468              122/2468                 1.17 (0.92--1.51)           0.206     
  Use for \>30 days       1092/29 489           1499/29 489              0.72 (0.66--0.78)           \<0.001   

###### 

Effect of Different Types of Perioperative Atenolol, Bisoprolol, Carvedilol, and Metoprolol Use on Mortality Among Patients With Diabetes Mellitus Undergoing Noncardiac Surgery

                          Beta‐Blocker Cohort   Matched Control Cohort   Propensity Score Matching             
  ----------------------- --------------------- ------------------------ --------------------------- --------- ---------
  In‐hospital mortality                                                                                        
  All                     872/31 957            1156/31 957              0.75 (0.68--0.82)           \<0.001   \<0.001
  Atenolol                290/13 556            459/13 556               0.62 (0.54--0.72)           \<0.001   
  Bisoprolol              289/11 100            399/11 100               0.72 (0.61--0.84)           \<0.001   
  Carvedilol              252/6039              254/6039                 0.99 (0.83--1.19)           0.928     
  Metoprolol              41/1262               44/1262                  0.93 (0.60--1.43)           0.741     
  30‐day mortality                                                                                             
  All                     1234/31 957           1621/31 957              0.75 (0.70--0.81)           \<0.001   \<0.001
  Atenolol                429/13 556            634/13 556               0.67 (0.59--0.75)           \<0.001   
  Bisoprolol              403/11 100            562/11 100               0.71 (0.62--0.81)           \<0.001   
  Carvedilol              350/6039              348/6039                 1.01 (0.86--1.17)           0.938     
  Metoprolol              52/1262               77/1262                  0.66 (0.46--0.95)           0.025     

In contrast, the analyses stratified according to perioperative initiation time of other beta‐blockers showed use of other beta‐blockers within 30 days before surgery was associated with increased risks of in‐hospital mortality (OR 1.56, 95% CI 1.21--2.02, *P* ~interaction~\<0.001) and 30‐day mortality (OR 1.39, 95% CI 1.12--1.72, *P* ~interaction~\<0.001) (Table [5](#jah31971-tbl-0005){ref-type="table-wrap"}).

###### 

Effect of Different Duration of Perioperative Other Beta‐Blocker Use on Mortality Among Patients With Diabetes Mellitus Undergoing Noncardiac Surgery

                          Beta‐Blocker Cohort   Matched Control Cohort   Propensity Score Matching           
  ----------------------- --------------------- ------------------------ --------------------------- ------- ---------
  In‐hospital mortality                                                                                      
  All                     640/18 995            639/18 995               1.00 (0.90--1.12)           0.977   \<0.001
  Use for ≤30 days        155/3222              101/3222                 1.56 (1.21--2.02)           0.001   
  Use for \>30 days       485/15 773            538/15 773               0.90 (0.79--1.02)           0.092   
  30‐day mortality                                                                                           
  All                     865/18 995            873/18 995               0.99 (0.90--1.09)           0.844   \<0.001
  Use for ≤30 days        206/3222              151/3222                 1.39 (1.12--1.72)           0.003   
  Use for \>30 days       659/15 773            722/15 773               0.91 (0.82--1.01)           0.083   

Associations Between Perioperative Initiation Time of Any Beta‐Blocker and In‐Hospital and 30‐Day Mortality Risks {#jah31971-sec-0014}
-----------------------------------------------------------------------------------------------------------------

In the subgroup analysis, vascular surgery showed significant interaction (*P* ~interaction~=0.044) ([Figure](#jah31971-fig-0001){ref-type="fig"}; Table S4). Perioperative beta‐blockers in patients with DM undergoing vascular surgery had greater 30‐day mortality risk reduction (OR 0.74, 95% CI 0.68--0.82) than those undergoing nonvascular surgery (OR 0.85, 95% CI 0.78--0.92).

![Subgroup analysis of risk of using any beta‐blockers for 30‐day mortality among patients with diabetes mellitus undergoing noncardiac surgery. HR indicates hazard ratio.](JAH3-6-e004392-g001){#jah31971-fig-0001}

Discussion {#jah31971-sec-0015}
==========

To our knowledge, this population‐based study is the largest to explore associations between perioperative beta‐blocker initiation time and mortality in patients with DM undergoing noncardiac surgery in a real‐world setting. We found that the use of cardioprotective beta‐blockers for \>30 days before noncardiac surgery was associated with lower risks of in‐hospital and 30‐day mortality in patients with DM. However, the use of these beta‐blockers within 30 days before surgery was not associated with lower risks of mortality. Moreover, the use of other beta‐blockers before noncardiac surgery was not associated with improved outcomes; it was even associated with increased mortality significantly in those receiving treatment within 30 days before surgery. The interaction results showed a lower mortality risk in patients treated with perioperative beta‐blockers in patients undergoing vascular surgery than in those undergoing nonvascular surgery.

A multicenter study of 200 patients with CHD who received atenolol before and during hospitalization showed that this treatment improved survival in patients with CHD and DM by ≈75% (hazard ratio 0.25).[8](#jah31971-bib-0008){ref-type="ref"} That study, however, was limited by the small sample of patients with DM (only one‐third of the study population), and the attribution of such a large benefit to a single drug is somewhat implausible. Conversely, the DIPOM trial found that perioperative metoprolol use from the day before surgery (maximum 8 perioperative days) did not significantly affect mortality.[9](#jah31971-bib-0009){ref-type="ref"} Notably, the DIPOM trial is limited by a small number of events, and that is what led to the wide CIs and may have affected the precision of results. These findings are similar to those of the present study, suggesting that short‐term perioperative use of beta‐blockers confers no survival benefit in patients with DM.

Meta‐analysis of randomized controlled trials showed that perioperative beta‐blocker initiation increased mortality by 27%.[26](#jah31971-bib-0026){ref-type="ref"} However, most randomized controlled trials enrolled in that analysis included patients using beta‐blockers ≤1 day before noncardiac surgery.[1](#jah31971-bib-0001){ref-type="ref"} Thus, until the results of further large randomized controlled trials focusing specifically on patients with DM become available, our findings regarding the survival benefits conferred by perioperative beta‐blocker use according to initiation time in a nationwide population are of importance in this field. Our findings help address the current knowledge gap by showing that short‐term (≤30 days) preoperative cardioprotective beta‐blocker use had no apparent survival benefit in patients with DM, whereas long‐term (\>30 days) use was associated with a decreased risk of mortality. In addition, the use of other beta‐blockers within 30 days before surgery may be harmful.

Controversy exists regarding the efficacy of the use of specific beta‐blockers before noncardiac surgery in terms of all‐cause mortality. The POISE‐1 (Perioperative Ischemic Evaluation 1) trial, which included 8351 participants, showed that perioperative use of extended‐release metoprolol succinate increased the risk of mortality in patients undergoing noncardiac surgery.[27](#jah31971-bib-0027){ref-type="ref"} This finding is in contrast to results from the Perioperative Beta‐Blockade,[28](#jah31971-bib-0028){ref-type="ref"} DIPOM,[9](#jah31971-bib-0009){ref-type="ref"} and Metoprolol after Vascular Surgery[29](#jah31971-bib-0029){ref-type="ref"} trials. The different results obtained in the POISE‐1 trial may be attributable to the use of high‐dose, long‐acting metoprolol shortly prior to surgery, although that seldom occurs in real‐world practice. In our study, we noted that significant interaction between perioperative beta‐blocker use and vascular surgery affected the risk of all‐cause mortality; the survival benefit of beta‐blocker therapy was more prominent in patients with DM undergoing vascular surgery.

The main strength of this study is the examination of data from a large sample drawn from the population of all patients with DM undergoing all types of noncardiac surgery between 2000 and 2011 in Taiwan. Current guidelines recommend perioperative beta‐blocker initiation before noncardiac surgery in patients with ischemic heart disease and those undergoing high‐risk surgery.[1](#jah31971-bib-0001){ref-type="ref"}, [2](#jah31971-bib-0002){ref-type="ref"} Some limitations of this study should be addressed. First, the database lacked some relevant information about heart rate, the occurrence of atrioventricular block, and severe hypotension, as well as the diagnosis and severity of DM, such as hemoglobin A1c and glucose measurements; however, the accuracy of DM diagnoses in Taiwan\'s NHI research database has been validated.[13](#jah31971-bib-0013){ref-type="ref"} In addition, the duration and severity of DM according to the adapted Diabetes Complications Severity Index have been found to be comparable between patients receiving and not receiving beta‐blockers.[23](#jah31971-bib-0023){ref-type="ref"} Second, although we used propensity score--matched analysis to provide a balance between patients with DM who did and did not receive beta‐blockers, given the retrospective nature of the study, selection bias and unmeasured confounding could not be completely eliminated. Consequently, further prospective randomized clinical trials are warranted to validate our findings. Third, because we focused only on the DM population, the observed effects of beta‐blocker initiation time may not be generally applicable to populations without DM.

In conclusion, the short‐term (≤30 days preoperatively) use of cardioprotective beta‐blockers was not associated with a decreased risk of mortality in patients with DM undergoing noncardiac surgery; however, long‐term (\>30 days preoperatively) use of cardioprotective beta‐blockers was associated with a decreased risk of mortality.
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